Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 8.41
CLDN's Cash to Debt is ranked higher than
68% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. CLDN: 8.41 )
CLDN' s 10-Year Cash to Debt Range
Min: 8.41   Max: No Debt
Current: 8.41

Z-Score: -0.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -82.07
CLDN's ROE (%) is ranked higher than
59% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. CLDN: -82.07 )
CLDN' s 10-Year ROE (%) Range
Min: -320.68   Max: -320.68
Current: -82.07

ROA (%) -53.22
CLDN's ROA (%) is ranked higher than
60% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. CLDN: -53.22 )
CLDN' s 10-Year ROA (%) Range
Min: -87.49   Max: -61.4
Current: -53.22

-87.49
-61.4
ROC (Joel Greenblatt) (%) -6858.75
CLDN's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. CLDN: -6858.75 )
CLDN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26139.34   Max: -6165.83
Current: -6858.75

-26139.34
-6165.83
» CLDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CLDN Guru Trades in

CLDN Guru Trades in

Q1 2014

CLDN Guru Trades in Q1 2014

Steven Cohen 34,821 sh (New)
» More
Q4 2014

CLDN Guru Trades in Q4 2014

Jim Simons 21,600 sh (New)
Steven Cohen 7,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CLDN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.80
CLDN's P/B is ranked higher than
99% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. CLDN: 0.80 )
CLDN' s 10-Year P/B Range
Min: 0   Max: 6.5
Current: 0.8

0
6.5
Current Ratio 13.33
CLDN's Current Ratio is ranked higher than
91% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CLDN: 13.33 )
CLDN' s 10-Year Current Ratio Range
Min: 2.83   Max: 18.52
Current: 13.33

2.83
18.52
Quick Ratio 13.33
CLDN's Quick Ratio is ranked higher than
91% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. CLDN: 13.33 )
CLDN' s 10-Year Quick Ratio Range
Min: 2.83   Max: 18.52
Current: 13.33

2.83
18.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.90
CLDN's Price/Net Cash is ranked higher than
100% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. CLDN: 0.90 )
CLDN' s 10-Year Price/Net Cash Range
Min: 6.69   Max: 6.69
Current: 0.9

Price/Net Current Asset Value 0.90
CLDN's Price/Net Current Asset Value is ranked higher than
100% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. CLDN: 0.90 )
CLDN' s 10-Year Price/Net Current Asset Value Range
Min: 6.4   Max: 6.4
Current: 0.9

Price/Tangible Book 0.80
CLDN's Price/Tangible Book is ranked higher than
99% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. CLDN: 0.80 )
CLDN' s 10-Year Price/Tangible Book Range
Min: 2.37   Max: 6.11
Current: 0.8

2.37
6.11
Earnings Yield (Greenblatt) -13.40
CLDN's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. CLDN: -13.40 )
CLDN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.9   Max: 0
Current: -13.4

-14.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:72C.Germany,
Celladon Corp was incorporated in California on December 21, 2000 and reincorporated in Delaware in April 2012. The Company is a clinical-stage biotechnology with industry expertise in the development of cardiovascular gene therapy. Its programs target sarco/endoplasmic reticulum Ca2+ -ATPase, or SERCA, enzymes, which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a clinical syndrome characterized by poor heart function resulting in inadequate blood flow to meet the body's metabolic needs, as well as blood vessel health, diabetes and neurodegenerative diseases. SERCA2a, an enzyme that becomes deficient in patients with heart failure, was scientifically validated as a molecular target for heart failure in the 1990s and became a focus of internal discovery efforts for many large pharmaceutical companies. Its therapeutic portfolio includes both gene therapies and small molecule compounds targeting diseases characterized by SERCA enzyme deficiency. MYDICAR, its advanced product candidate, uses gene therapy to target SERCA2a. Its suppliers include Lonza and Novasep, for the manufacturing of its viral vectors and product candidates for clinical testing purposes. The Company expect to rely upon Lonza, Novasep, and/or other third parties to produce materials required for the commercial production of its product candidates and companion diagnostic. Its commercial strategy involving a progressive build out of commercial infrastructure in the United States covering key prescribers and centers of excellence is one that they can realistically pursue. The Company face potential competition from many different sources, including larger and funded pharmaceutical companies. Its competitors include Renova Therapeutics, NanoCor Therapeutics, Juventas Therapeutics, VentriNova and Beat BioTherapeutics. Biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. The Company requires to obtain FDA approval before clinical testing of a biological product begins, and each clinical trial protocol for a gene therapy product is reviewed by the FDA and, in some instances, the U.S. National Institutes of Health, or NIH, through its Recombinant DNA Advisory Committee, or RAC.
» More Articles for CLDN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CELLADON CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated... Apr 30 2015
The Zacks Analyst Blog Highlights: Amgen, Celladon, Biogen, Celgene and Gilead - Press Releases Apr 30 2015
The Zacks Analyst Blog Highlights: Amgen, Celladon, Kite Pharma, Pharmacyclics and Vertex... Apr 30 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
Most active Nasdaq-traded stocks Apr 29 2015
Should You Still Invest in Biotech Mutual Funds? - Mutual Fund Commentary Apr 29 2015
3 Stable Large-Cap Biotech Stocks to Buy Now - Analyst Blog Apr 29 2015
The Zacks Analyst Blog Highlights: Celladon, Amgen, Biogen and Alnylam Pharmaceuticals - Press... Apr 29 2015
Biotech Stock Roundup: Weakness in Biotech Sector on Amgen & Celladon News - Analyst Blog Apr 29 2015
Celladon's Advanced Heart Failure Study Fails, Shares Crash - Analyst Blog Apr 28 2015
5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog Apr 28 2015
3 Biotech Stocks Still Attractive After Monday's Sell-Off - Analyst Blog Apr 28 2015
Stock Market News for April 28, 2015 - Market News Apr 28 2015
Zacks Investment Ideas feature highlights: Celladon, Novavax and Bluebird Bio - Press Releases Apr 28 2015
Celladon downgraded by H.C. Wainwright Apr 28 2015
US STOCKS-Wall St ends down as biotechs drop 4 pct; Apple up late Apr 27 2015
US STOCKS-Wall St ends down as biotechs drop 4 pct; Apple up late Apr 27 2015
DuPont and Mylan are big market movers Apr 27 2015
DuPont and Mylan are big market movers Apr 27 2015
US STOCKS-Wall St ends down as biotechs drop 4 pct Apr 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK